Related Experiment Videos
Transient focal neurologic deficits complicating interleukin-2 therapy
J T Bernard1, S Ameriso, R A Kempf
1Department of Neurology, University of Southern California School of Medicine, Los Angeles 90033.
Neurology
|January 1, 1990
Summary
Interleukin-2 treatment can cause temporary, focal neurological deficits in patients. These episodes, including blindness and vision loss, may stem from interleukin-2-induced endothelial cell activation.
Area of Science:
- Neuro-oncology
- Immunotherapy
- Vascular Neurology
Background:
- Interleukin-2 (IL-2) is a cytokine used in cancer immunotherapy.
- Neurological side effects of IL-2 therapy are rare but can be severe.
- Understanding the mechanisms of IL-2-induced neurotoxicity is crucial for patient safety.
Observation:
- Two patients undergoing IL-2 treatment experienced transient, focal neurological episodes.
- One patient presented with recurrent monocular blindness (transient vision loss in one eye).
- The second patient experienced recurrent homonymous quadrantanopia (vision loss in corresponding visual fields).
Findings:
- The observed neurological deficits were repetitive and stereotyped.
- These episodes occurred specifically during IL-2 therapy.
- The study hypothesizes that endothelial cell activation by IL-2 triggers these neurological events.
Implications:
- IL-2 therapy may be associated with specific, transient visual and neurological disturbances.
- Endothelial cell activation is a potential mechanism for IL-2 neurotoxicity.
- Further research is needed to confirm this mechanism and develop preventative strategies for patients receiving IL-2.